Guardian Pharmacy Services, Inc. (NYSE:GRDN) Receives $32.00 Average Price Target from Analysts

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) have earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $32.00.

A number of equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research report on Monday, December 29th. Wall Street Zen raised shares of Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a report on Monday, November 17th. Stephens boosted their price target on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, January 14th. Finally, Truist Financial increased their price objective on shares of Guardian Pharmacy Services from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, November 14th.

Guardian Pharmacy Services Stock Down 1.2%

NYSE:GRDN opened at $33.70 on Friday. Guardian Pharmacy Services has a 52 week low of $17.78 and a 52 week high of $37.43. The company has a fifty day simple moving average of $30.57 and a two-hundred day simple moving average of $27.75. The company has a market cap of $2.13 billion, a price-to-earnings ratio of 53.49 and a beta of 0.96.

Guardian Pharmacy Services (NYSE:GRDN) last released its earnings results on Monday, November 10th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.01. Guardian Pharmacy Services had a return on equity of 30.29% and a net margin of 2.90%.The firm had revenue of $377.43 million during the quarter, compared to analyst estimates of $381.16 million. On average, analysts expect that Guardian Pharmacy Services will post 0.87 EPS for the current year.

Institutional Trading of Guardian Pharmacy Services

Institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue acquired a new position in shares of Guardian Pharmacy Services during the 3rd quarter worth about $30,000. Parkside Financial Bank & Trust purchased a new stake in Guardian Pharmacy Services during the second quarter worth approximately $41,000. Ameritas Investment Partners Inc. boosted its holdings in Guardian Pharmacy Services by 26.5% in the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock valued at $43,000 after purchasing an additional 345 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Guardian Pharmacy Services in the second quarter valued at approximately $43,000. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in Guardian Pharmacy Services by 76.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company’s stock valued at $52,000 after purchasing an additional 1,062 shares during the last quarter.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.